Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study

NCT03009396 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT03009396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 3
Overall status
Completed
Start date
March 18, 2017
Completion date
August 19, 2019
Enrollment
54 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease